Clinical implications of der(9q) deletions detected through dual-fusion fluorescence in situ hybridization in patients with chronic myeloid leukemia

Cancer Genetics and Cytogenetics

Volumn 178, Issue 1, 2007, Pages 49-56

  Guimarães Vaz de Campos, Mireille ^a   Montesano, Fábio Tadeu ^a   Rodrigues, Maria Madalena ^a   de Lourdes Lopes Ferrari Chauffaille, Maria ^a  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN;

ADULT; ARTICLE; CHROMOSOME 9Q; CHROMOSOME DELETION; CHRONIC MYELOID LEUKEMIA; COMPARATIVE STUDY; CONTROLLED STUDY; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS;

ADULT; CHROMOSOME ABERRATIONS; CHROMOSOMES, HUMAN, PAIR 9; FEMALE; GENE DELETION; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; LEUKEMIA, MYELOID, CHRONIC; MALE; MIDDLE AGED; NUCLEIC ACID HYBRIDIZATION; RISK FACTORS; TIME FACTORS; TRANSLOCATION, GENETIC; TREATMENT OUTCOME;

EID: 34548748074     PISSN: 01654608     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cancergencyto.2007.06.013     Document Type: Article

References (31)

1. Popenoe D.W., Schaefer-Rego K., Mears J.G., Bank A., and Leibowitz D. Frequent and extensive deletion during the 9,22 translocation in CML. Blood 68 5 (1986 Nov) 1123-1128
2. Dewald G.W., Wyatt W.A., Juneau A.L., Carlson R.O., Zinsmeister A.R., Jalal S.M., Spurbeck J.L., and Silver R.T. Highly sensitive fluorescence in situ hybridization method to detect double BCR/ABL fusion and monitor response to therapy in chronic myeloid leukemia. Blood 91 9 (1998) 3357-3365
3. Lemaire V., Jamar M., Evrard A., Augenbron V., Verheyen V., Koulisher L., and Herens C. Deletions of 9q proximal to the ABL gene in standard and variant Philadelphia translocations: a new anomaly observed in more than 10% of CML patients. Cytogenet Cell Genet 85 (1999) 77 (abstract p. 303)
4. Sinclair P.B., Nacheva E.P., Leversha M., Telford N., Chang J., Reid A., et al. Large deletions at the t(9;22) breakpoint are common and may identify a poor-prognosis subgroup of patients with chronic myeloid leukemia. Blood 95 3 (2000) 738-743
5. Kolomietz E., Al-Maghrabi J., Brennan S., Karaskova J., Minkin S., Lipton J., et al. Primary chromosomal rearrangements of leukemia are frequently accompanied by extensive submicroscopic deletions and may lead to altered prognosis. Blood 97 11 (2001) 3581-3588
6. Cohen N., Rozenfeld-Granot G., Hardan I., Brok-Simoni F., Amariglio N., Rechavi G., et al. Subgroup of patients with Philadelphia-positive chronic myelogenous leukemia characterized by a deletion of 9q proximal to ABL gene: expression profiling, resistance to interferon therapy, and poor prognosis. Cancer Genet Cytogenet 128 2 (2001) 114-119
7. Huntly B.J., Bench A.J., Delabesse E., Reid A.G., Li J., Scott M.A., et al. Derivative chromosome 9 deletions in chronic myeloid leukemia: poor prognosis is not associated with loss of ABL-BCR expression, elevated BCR-ABL levels or karyotypic instability. Blood 99 12 (2002) 4547-4553
8. Mohr B., Bornhauser M., Platzbecker U., Freiberg-Richter J., Naumann R., Prange-Krex G., et al. Problems with interphase fluorescence in situ hybridization in detecting BCR/ABL-positive cells in some patients using a novel technique with extra signals. Cancer Genet Cytogenet 127 2 (2001) 111-117
9. Lee D.S., Lee Y.S., Yun Y.S., Kim Y.R., Jeong S.S., Lee Y.K., et al. A study on the incidence of ABL gene deletion on derivative chromosome 9 in chronic myelogenous leukemia by interphase fluorescence in situ hybridization and its association with disease progression. Genes Chromosomes Cancer 37 3 (2003) 291-299
10. Lee Y.K., Kim Y.R., Min H.C., Oh B.R., Kim T.Y., Kim Y.S., et al. Deletion of any part of the BCR or ABL gene on the derivative chromosome 9 is a poor prognostic marker in chronic myelogenous leukemia. Cancer Genet Cytogenet 166 1 (2006) 65-73
11. Gonzalez F.A., Anguita E., Mora A., Asenjo S., Lopez I., Polo M., et al. Deletion of BCR region 3′ in chronic myelogenous leukemia. Cancer Genet Cytogenet 130 1 (2001) 68-74
12. Huntly B.J., Reid A.G., Bench A.J., Campbell L.J., Telford N., Shepherd P., et al. Deletions of the derivative chromosome 9 occur at the time of the Philadelphia translocation and provide a powerful and independent prognostic indicator in chronic myeloid leukemia. Blood 98 6 (2001) 1732-1738
13. de la Fuente J., Merx K., Steer E.J., Muller M., Szydlo R.M., Maywald O., et al. ABL-BCR expression does not correlate with deletions on the derivative chromosome 9 or survival in chronic myeloid leukemia. Blood 98 9 (2001) 2879-2880
14. Loncarevic I.F., Romer J., Starke H., Heller A., Bleck C., Ziegler M., et al. Heterogenic molecular basis for loss of ABL1-BCR transcription: deletions in der(9)t(9;22) and variants of standard t(9;22) in BCR-ABL1-positive chronic myeloid leukemia. Genes Chromosomes Cancer 34 2 (2002) 193-200
15. Cohen N., Amariglio N., Rechavi G., Trakhtenbrot L., and Hardan I. Simultaneous detection of deletions of 9q and 22q in a subgroup of chronic myelocytic leukemia Philadelphia-positive patients by a novel probe. Cancer Genet Cytogenet 141 1 (2003) 89-90
16. Fournier M., Lacrosse S., Jamar M., Bours V., and Herens C. Deletions of the 3′BCR and 5′ABL regions in patients with Philadelphia-positive chronic myeloid leukemia: a one-step process occurring in about 10% of the cases without any evidence of genetic instability in the target cells. Cancer Genet Cytogenet 160 2 (2005) 184-187
17. Lim T.H., Tien S.L., Lim P., and Lim A.S. The incidence and patterns of BCR/ABL rearrangements in chronic myeloid leukaemia (CML) using fluorescence in situ hybridisation (FISH). Ann Acad Med Singapore 34 9 (2005) 533-538
18. Wan T.S., Ma S.K., Au W.Y., and Chan L.C. Derivative chromosome 9 deletions in chronic myeloid leukaemia: interpretation of atypical D-FISH pattern. J Clin Pathol 56 6 (2003) 471-474
19. Huntly B.J., Bench A., and Green A.R. Double jeopardy from a single translocation: deletions of the derivative chromosome 9 in chronic myeloid leukemia. Blood 102 4 (2003) 1160-1168
20. In: Jaffe E.S., Harris N.L., Stein H., and Vardiman J.W. (Eds). Pathology and genetics of tumors of haematopoietic and lymphoid tissues - World Health Organization Classification of Tumors (2001), IARC Press Lyon 53
21. Sokal J.E., Baccarani M., Russo D., et al. Staging and prognosis in chronic myelogenous leukemia. Semin Hematol 25 1 (1988) 49-61
22. Hasford J., Pfirmann M., Hehlmann R., Allan N.C., Baccarani M., Kluin-Nelemans J., Alimena G., Steegmann J., and Ansari H. A new prognostic score for the survival of patients with chronic myeloid leukemia. J Natl Cancer Inst 90 (1998) 850
23. Chauffaille M.L., Figueiredo M.S., Beltrani R., Antunes S.V., Yamamoto M., and Kerbauy J. Acute promyelocytic leukemia: the study of t(15;17) translocation by fluorescent in situ hybridization, reverse transcriptase-polymerase chain reaction and cytogenetic techniques. Braz J Med Biol Res 34 6 (2001) 735-743
24. Fourouclas N., Campbell P.J., Bench A.J., Swanton S., Baxter E.J., Huntly B.J., et al. Size matters: the prognostic implications of large and small deletions of the derivative 9 chromosome in chronic myeloid leukemia. Haematologica 91 7 (2006) 952-955
25. Storlazzi C.T., Specchia G., Anelli L., Albano F., Pastore D., Zagaria A., et al. Breakpoint characterization of der(9) deletions in chronic myeloid leukemia patients. Genes Chromosomes Cancer 35 3 (2002) 271-276
26. Yoong Y., VanDeWalker T.J., Carlson R.O., Dewald G.W., and Tefferi A. Clinical correlates of submicroscopic deletions involving the ABL-BCR translocation region in chronic myeloid leukemia. Eur J Haematol 74 2 (2005) 124-127
27. Primo D., Tabernero M.D., Rasillo A., Sayagues J.M., Espinosa A.B., Chillon M.C., et al. Patterns of BCR/ABL gene rearrangements by interphase fluorescence in situ hybridization (FISH) in BCR/ABL+ leukemias: incidence and underlying genetic abnormalities. Leukemia 17 6 (2003) 1124-1129
28. Huntly B.J., Guilhot F., Reid A.G., Vassiliou G., Hennig E., Franke C., et al. Imatinib improves but may not fully reverse the poor prognosis of patients with CML with derivative chromosome 9 deletions. Blood 102 6 (2003) 2205-2212
29. Kolomietz E., Marrano P., Yee K., Thai B., Braude I., Kolomietz A., et al. Quantitative PCR identifies a minimal deleted region of 120 kb extending from the Philadelphia chromosome ABL translocation breakpoint in chronic myeloid leukemia with poor outcome. Leukemia 17 7 (2003) 1313-1323
30. Markovic V.D., Bouman D., Bayani J., Al-Maghrabi J., Kamel-Reid S., and Squire J.A. Lack of BCR/ABL reciprocal fusion in variant Philadelphia chromosome translocations: a use of double fusion signal FISH and spectral karyotyping. Leukemia 14 6 (2000) 1157-1160
31. Quintas-Cardama A., Kantarjian H., Talpaz M., O'Brien S., Garcia-Manero G., Verstovsek S., Rios M.B., Hayes K., Glassman A., Bekele B.N., Zhou X., and Cortes J. Imatinib mesylate therapy may overcome the poor prognostic significance of deletions of derivative chromosome 9 in patients with chronic myelogenous leukemia. Blood 105 6 (2005) 2281-2286